Core Viewpoint - The China Securities Regulatory Commission (CSRC) has requested Jiangsu Dingtai Pharmaceutical Research (Dingtai Yao Yan) to provide supplementary explanations regarding equity changes and other matters as part of its application for listing on the Hong Kong Stock Exchange [1][2][3] Group 1: Equity Changes - The CSRC requires Dingtai Yao Yan to clarify the pricing basis for past capital increases and equity transfers, including whether actual contributions were made and if there are any unfulfilled obligations or defects in the contribution methods [1] - The company must provide updates on the overseas investment procedures related to the establishment of Hong Kong Dingtai and the ODI procedures concerning the investment in Xellar Ltd [1] - A review of historical shareholding arrangements and the involvement of external advisors in employee stock ownership plans is mandated to ensure compliance and identify any potential conflicts of interest [1][2] Group 2: Shareholder Situation - Dingtai Yao Yan is required to justify the reasonableness of the share prices for new shareholders over the past 12 months and to clarify any discrepancies in these prices [2] - The company must confirm whether shares held by four shareholders obtained through the share transfer system are subject to pledges, freezes, or other rights defects [2] Group 3: Business Operations - The company needs to detail its business scope, which includes medical research, gene diagnosis and treatment technology development, and breeding of protected wildlife, ensuring that it has the necessary qualifications and complies with foreign investment policies [2] - A legal opinion is required to confirm whether the company or its subsidiaries fall under any prohibitive circumstances for overseas issuance and listing as per regulatory guidelines [2][3] Group 4: Listing and Full Circulation - Dingtai Yao Yan must explain any inconsistencies between the proposed listing plan and the materials submitted, including the prospectus [3] - The company is also required to disclose the status of shares held by shareholders participating in the "full circulation" and whether these shares are subject to any rights defects [3] - Details regarding the company's previous listing on the National Equities Exchange and Quotations (NEEQ) and the reasons for its termination, as well as plans for A-share listing, must be provided [3]

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has requested Jiangsu Dingtai Pharmaceutical Research (Dingtai) to provide supplementary explanations regarding equity changes and other matters as part of its listing application on the Hong Kong Stock Exchange [1][2][3] Group 1: Equity Changes - Dingtai is required to clarify the pricing basis for its past capital increases and equity transfers, including whether actual contributions were made and if there are any unfulfilled obligations or flaws in the contribution methods [1] - The company must provide updates on the overseas investment procedures related to the establishment of Hong Kong Dingtai and the investment in Xellar Ltd. [1] - A thorough investigation into the historical shareholding arrangements and the involvement of external advisors in employee stock ownership plans is mandated to ensure compliance and identify any potential conflicts of interest [1][2] Group 2: Shareholder Situation - Dingtai must justify the reasonableness of the share prices for new shareholders over the past 12 months and assess any discrepancies that may indicate potential benefits being transferred [2] - The company is required to confirm whether shares held by four shareholders obtained through the share transfer system are subject to pledges, freezes, or other rights defects [2] Group 3: Business Operations - Dingtai needs to detail its business scope, including medical research, gene diagnosis and treatment technology development, and whether it has obtained necessary qualifications and licenses for these operations [2] - The company must ensure that its business activities comply with foreign investment access policies and provide a basis for such judgments [2] Group 4: Listing and Full Circulation - Dingtai is instructed to explain any inconsistencies between the listing plan and the materials submitted for record-keeping, as well as the status of shares held by shareholders participating in the "full circulation" [3] - The company must provide details on its previous listing on the National Equities Exchange and Quotations (NEEQ) and the reasons for its termination, along with plans for A-share listing [3] Group 5: Company Overview - Dingtai, established in 2008, is a contract research organization (CRO) focused on providing integrated solutions based on disease biology for global pharmaceutical companies and research institutions [3]

Group 1: Recent IPOs - Minglue Technology, a data intelligence application software company, successfully listed on the Hong Kong Stock Exchange, raising approximately HKD 1.018 billion with a market capitalization of HKD 31.301 billion [1] - Seres, a new energy vehicle brand, completed its IPO on the Hong Kong Stock Exchange, raising around HKD 14.283 billion and achieving a market capitalization of HKD 247.6 billion [2] - Joyson Electronics, a provider of automotive technology solutions, successfully listed on the Hong Kong Stock Exchange, raising approximately HKD 3.412 billion with a market capitalization of HKD 31.388 billion [3] - Wangshan Wangshui, a biopharmaceutical company, completed its IPO on the Hong Kong Stock Exchange, raising about HKD 0.587 billion and achieving a market capitalization of HKD 13.743 billion [4] - WeRide, an L4 autonomous driving technology company, successfully listed on the Hong Kong Stock Exchange, raising approximately HKD 2.392 billion with a market capitalization of HKD 25.049 billion [5] Group 2: Companies Filing for IPO - Xinde Semiconductor, a semiconductor packaging and testing solutions provider, filed for an IPO on the Hong Kong Stock Exchange [6] - Haiguangxin, a provider of optical interconnect products, submitted an IPO application to the Hong Kong Stock Exchange, ranking 10th globally in professional optical module providers by revenue for 2024 [8] - Dingtai Pharmaceutical, a contract research organization, filed for an IPO on the Hong Kong Stock Exchange, offering integrated solutions for pharmaceutical companies and research institutions [9] - Haote Energy, an energy management solutions provider, submitted an IPO application to the Hong Kong Stock Exchange, focusing on data center energy management [10] - Guoxia Technology, a renewable energy solutions provider, filed for an IPO on the Hong Kong Stock Exchange, specializing in energy storage systems [11] - Tiantong Vision, an L4 solution provider, submitted an IPO application to the Hong Kong Stock Exchange, offering comprehensive intelligent driving solutions [12] - Lupeng Pharmaceutical, a platform-based pharmaceutical company, filed for an IPO on the Hong Kong Stock Exchange, focusing on high bioavailability oral drugs [13][14] - Libang Pharmaceutical, a biopharmaceutical company specializing in kidney disease, submitted an IPO application to the Hong Kong Stock Exchange [15] - FSTech, a provider of electric drive solutions, filed for an IPO on the Hong Kong Stock Exchange, ranking second in China's industrial control sector by revenue for 2024 [16] - Ketao Co., a smart parking space operator, refiled for an IPO on the Hong Kong Stock Exchange after a previous application expired [17] - Zhihui Interconnect, an AI company, submitted an IPO application to the Hong Kong Stock Exchange, focusing on urban traffic management solutions [18] - Taotao Vehicle, an electric mobility company, filed for an IPO on the Hong Kong Stock Exchange, ranking second globally in the electric low-speed vehicle industry by revenue for 2024 [19] - Nanhua Futures, a financial services provider, refiled for an IPO on the Hong Kong Stock Exchange after a previous application expired [20] Group 3: Companies Passing Hearings - Haiwei Electronics, a capacitor film manufacturer, passed the listing hearing on the Hong Kong Stock Exchange, ranking second in China by capacitor film sales volume for 2024 [21] Group 4: Companies Approved for Filing - Xidi Zhijia received approval for overseas issuance and "full circulation" of unlisted shares from the China Securities Regulatory Commission [22]

Core Viewpoint - Jiangsu Dingtai Pharmaceutical Research (Group) Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, with Citigroup and Haitong International acting as joint sponsors [1]. Company Overview - Established in 2008, Dingtai Pharmaceutical is a new type of Contract Research Organization (CRO) that provides integrated solutions based on disease biology for global pharmaceutical companies and research institutions. The company has transformed from a traditional CRO into a strategic R&D partner for clients [3]. - The company offers comprehensive non-clinical safety, efficacy, and drug metabolism and pharmacokinetics (DMPK) research, as well as integrated clinical trial services from proof of concept to pivotal trials, supporting clients throughout the entire lifecycle of drug development [3]. - Dingtai Pharmaceutical focuses on clinical value and has accumulated deep expertise and rich experience in cardiovascular metabolic diseases, central nervous system (CNS) diseases, ophthalmology, autoimmune diseases, and oncology [3]. Market Position - According to Frost & Sullivan, Dingtai Pharmaceutical is the largest CRO in China for non-clinical research in cardiovascular metabolic diseases based on projected revenue for 2024 [3]. - The company has built one of the most comprehensive non-human primate (NHP) disease model portfolios in China, ranking as the third-largest CRO in the field of efficacy research in China for 2024 [4]. Services and Capabilities - Dingtai Pharmaceutical's biomarker and translational medicine platform provides immunology, cellular, and molecular testing, supported by industry-leading sensitivity, robustness, and throughput characteristics in mass spectrometry bioanalysis [4]. - The company proactively monitors the progress of new therapies in key disease areas to anticipate industry trends and strategically expand its technical capabilities [4]. - Dingtai has extensive project experience in oligonucleotide therapies, monoclonal and bispecific antibodies, antibody-drug conjugates (ADC), and cell gene therapy (CGT) [4]. Client Base and Achievements - The company has established a loyal and diverse client base, including commercial-stage pharmaceutical companies, early-stage biotech firms, and well-known research institutions. Since its inception until October 24, 2025, Dingtai has provided non-clinical services to over 700 clients and clinical services to over 130 clients, assisting clients in obtaining over 200 approvals from the National Medical Products Administration (NMPA) and over 40 approvals from overseas regulatory agencies [5]. - Dingtai Pharmaceutical holds Good Laboratory Practice (GLP) certification and is recognized by the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC), enabling it to support clients in regulatory submissions in major global markets [5]. Financial Performance - The company's revenue for the years 2022, 2023, 2024, and the six months ending June 30, 2025, were approximately RMB 725 million, RMB 767 million, RMB 713 million, and RMB 377 million, respectively. The corresponding profits (losses) for the same periods were approximately RMB 143 million, -RMB 52 million, -RMB 252 million, and RMB 64 million [5][6].